Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition-Reference-Cited by-同舟云学术

Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition

Published:2011-10 Issue:4 Volume:1 Page:235-242
ISSN:1879-8500
Container-title:Practical Radiation Oncology
language:en
Short-container-title:Practical Radiation Oncology

Author:

Klayton Tracy L.,Ruth Karen,Buyyounouski Mark K.,Uzzo Robert G.,Wong Yu-Ning,Chen David Y.T.,Sobczak Mark,Peter Ruth,Horwitz Eric M.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference47 articles.

1. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy;Buyyounouski;Int J Radiat Oncol Biol Phys,2008

2. No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy;Faria;Urology,2006

3. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database;Kim-Sing;Int J Radiat Oncol Biol Phys,2004

4. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer;Zelefsky;J Clin Oncol,2005

5. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?;Kuban;Int J Radiat Oncol Biol Phys,2011

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commentary: On measurement error, PSA doubling time, and prostate cancer;Global Epidemiology;2023-12

2. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2023-08

3. Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14);Acta Oncologica;2023-04-03

4. Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer;SAGE Open Medicine;2023-01

5. Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula;European Journal of Epidemiology;2022-10-26